American Society of Hematology

Figure 2.

$Figure 2. Anti–Gr-1 treatment specifically depletes the granulocytic fraction of splenic CD11b+Gr-1+cells. (A) BW-Sp3 late progressors (tumor diameter ± 20 mm), 5 to 7 weeks after inoculation, were injected intraperitoneally with 100 μg purified and LPS-free anti–Gr-1 antibodies, and 24 hours later splenocytes were stained with PE-labeled anti-CD11b and FITC-labeled anti–Gr-1 or anti-Ly6G. Surface staining profiles are represented in dot plots. (B) SSC profile of cells gated in R1. (C) Cells prepared in panel A were incubated with purified anti-MCSFR, followed by PE-labeled anti–rat IgG and FITC-labeled anti–Gr-1. Histograms represent isotype (dotted line) and M-CSFR–specific (full line) staining on the Gr-1int–gated population. Profiles shown in panels A-C are representative of one anti–Gr-1–treated spleen of 4 investigated.$

Anti–Gr-1 treatment specifically depletes the granulocytic fraction of splenic CD11b⁺Gr-1⁺cells. (A) BW-Sp3 late progressors (tumor diameter ± 20 mm), 5 to 7 weeks after inoculation, were injected intraperitoneally with 100 μg purified and LPS-free anti–Gr-1 antibodies, and 24 hours later splenocytes were stained with PE-labeled anti-CD11b and FITC-labeled anti–Gr-1 or anti-Ly6G. Surface staining profiles are represented in dot plots. (B) SSC profile of cells gated in R1. (C) Cells prepared in panel A were incubated with purified anti-MCSFR, followed by PE-labeled anti–rat IgG and FITC-labeled anti–Gr-1. Histograms represent isotype (dotted line) and M-CSFR–specific (full line) staining on the Gr-1^int–gated population. Profiles shown in panels A-C are representative of one anti–Gr-1–treated spleen of 4 investigated.

This Feature Is Available To Subscribers Only